What is the catalog number for PF-04957325?

The catalog number for PF-04957325 is HY-15426.

What sizes are available for PF-04957325?

PF-04957325 is available in the following size(s): 1 mg, 10 mM - 1 mL, 5 mg, 10 mg, 50 mg, 100 mg.

How many pack sizes does PF-04957325 come in?

PF-04957325 is available in 6 different pack sizes.

Is PF-04957325 in stock?

PF-04957325 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures PF-04957325?

PF-04957325 is manufactured by QuantiMol.

What is the estimated delivery time for PF-04957325?

Estimated delivery time for PF-04957325 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for PF-04957325?

The safety data sheet for PF-04957325 is available here: http://file.medchemexpress.com/batch_PDF/HY-15426/PF-04957325-SDS-MedChemExpress.pdf.

PF-04957325

PF-04957325 is a highly potent and selective PDE8 inhibitor, with IC50s of 0.7 nM and 0.3 nM for PDE8A and PDE8B, respectively.

Product Specifications

CAS Number

1305115-80-3

UNSPSC

12352005

Hazard Statement

H242

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/PF-04957325.html

Purity

99.55

Solubility

DMSO : ≥ 100 mg/mL

Smiles

NC1=C(N=NN2C[C@H]3CN(CC4=NC=CS4)CCO3)C2=NC(C(F)(F)F)=N1

Molecular Formula

C14H15F3N8OS

Molecular Weight

400.38

Precautions

H242

References & Citations

[1]Vang AG, et al. Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation. Front Pharmacol. 2016 Aug 23;7:259.|[2]Dong H, et al. Inhibition of breast cancer cell migration by activation of cAMP signaling. Breast Cancer Res Treat. 2015 Jul;152 (1) :17-28.|[3]Tsai LC, et al. Regulation of adrenal steroidogenesis by the high-affinity phosphodiesterase 8 family. Horm Metab Res. 2012 Sep;44 (10) :790-4.|[4]Shimizu-Albergine M, et al. cAMP-specific phosphodiesterases 8A and 8B, essential regulators of Leydig cell steroidogenesis. Mol Pharmacol. 2012 Apr;81 (4) :556-66.